Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Research & Development (2023 - 2025)

Immunocore Holdings' Research & Development history spans 3 years, with the latest figure at $56.5 million for Q1 2025.

  • For Q1 2025, Research & Development fell 1.72% year-over-year to $56.5 million; the TTM value through Mar 2025 reached $221.2 million, changed N/A, while the annual FY2025 figure was $274.9 million, 23.73% up from the prior year.
  • Research & Development for Q1 2025 was $56.5 million at Immunocore Holdings, down from $60.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $60.8 million in Q4 2024 and bottomed at $36.6 million in Q1 2023.
  • The 3-year median for Research & Development is $52.8 million (2024), against an average of $50.5 million.
  • The largest annual shift saw Research & Development skyrocketed 57.11% in 2024 before it dropped 1.72% in 2025.
  • A 3-year view of Research & Development shows it stood at $38.2 million in 2023, then skyrocketed by 59.47% to $60.8 million in 2024, then decreased by 7.2% to $56.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Research & Development are $56.5 million (Q1 2025), $60.8 million (Q4 2024), and $52.8 million (Q3 2024).